LSBCF (LakeShore Biopharma Co) EBITDA Margin %: -46.73% (As of Mar. 2025)


What is LakeShore Biopharma Co EBITDA Margin %?

LakeShore Biopharma Co LSBCF EBITDA Margin % is -46.73% as of Mar. 2025. The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, LakeShore Biopharma Co ranks better than 61.48% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. LakeShore Biopharma Co's EBITDA for the six months ended in Mar. 2025 was $-15.67 Mil. LakeShore Biopharma Co's Revenue for the six months ended in Mar. 2025 was $33.52 Mil. Therefore, LakeShore Biopharma Co's EBITDA margin for the quarter that ended in Mar. 2025 was -46.73%.

LakeShore Biopharma Co  (OTCPK:LSBCF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

LakeShore Biopharma Co EBITDA Margin % Related Terms

LakeShore Biopharma Co EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co EBITDA Margin % Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
EBITDA Margin %
-45.43 -13.36 -11.18 -64.29 -7.89

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only -34.31 -52.16 -75.33 7.63 -46.73

LSBCF vs ACUT, PPCB, ENSC: EBITDA Margin % Comparison

For the Biotechnology subindustry, LakeShore Biopharma Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's EBITDA Margin % falls into.


LakeShore Biopharma Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

LakeShore Biopharma Co's EBITDA Margin % for the fiscal year that ended in Mar. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2025 )/Revenue (A: Mar. 2025 )
=-6.696/84.831
=-7.89 %

LakeShore Biopharma Co's EBITDA Margin % for the quarter that ended in Mar. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=-15.665/33.523
=-46.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -46.73% mean?
LakeShore Biopharma Co (LSBCF) has a EBITDA Margin % of -46.73% as of Mar. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LakeShore Biopharma Co and its competitors. According to the industry distribution chart, LakeShore Biopharma Co ranks #364 out of 945 companies in the Biotechnology industry, placing it in the top 38.5%.
Is LakeShore Biopharma Co's EBITDA Margin % too high?
LakeShore Biopharma Co's current EBITDA Margin % is -46.73%. Based on the distribution chart, LakeShore Biopharma Co ranks #364 out of 945 companies in the Biotechnology industry, which is above the industry midpoint.
How does LakeShore Biopharma Co's EBITDA Margin % compare to ACUT and PPCB?
According to the Biotechnology industry distribution chart, LakeShore Biopharma Co ranks #364 out of 945 companies for EBITDA Margin %. This puts LakeShore Biopharma Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current EBITDA Margin % is -46.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current EBITDA Margin % of -46.73%. The current EBITDA Margin % is -46.73%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current EBITDA Margin % is -46.73% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.